Wider Access To Naloxone Overdose Medication On Tap In Meeting
This article was originally published in The Tan Sheet
Executive Summary
Behind-the-counter placement of opioid overdose treatment does not resonate with FDA, even as it wants to broaden availability. Naloxone administration has increased among non-medical personnel, which may be a reason FDA wants to discuss broader use of the product.
You may also be interested in...
Rescue Medicine Switch Concept Draws Criticism
FDA considers switching some prescription “antidotes” to restricted nonprescription status so consumers who can self-identify their need for the drugs and who previously had a prescription can easily access them during life-threatening events, says CDER Director Janet Woodcock.
US FDA Hopes Food, Inspection Office Reorg Bolsters Innovative Clinical Trial Adoption
Ensuring inspectors understand the innovative trial designs in use before an inspection will be important to increasing industry confidence in their use, CDER Director Patrizia Cavazzoni said.
US FDA's CDER Creates Quantitative Medicine Center Of Excellence; Job Includes AI Oversight
The group will coordinate quantitative medicine issues throughout the FDA's Center for Drug Evaluation and Research to help streamline drug development.